Literature DB >> 16002665

Inefficient cross-presentation limits the CD8+ T cell response to a subdominant tumor antigen epitope.

Pavel Otahal1, Sandra C Hutchinson, Lawrence M Mylin, M Judith Tevethia, Satvir S Tevethia, Todd D Schell.   

Abstract

CD8(+) T lymphocytes (T(CD8)) responding to subdominant epitopes provide alternate targets for the immunotherapy of cancer, particularly when self-tolerance limits the response to immunodominant epitopes. However, the mechanisms that promote T(CD8) subdominance to tumor Ags remain obscure. We investigated the basis for the lack of priming against a subdominant tumor epitope following immunization of C57BL/6 (B6) mice with SV40 large tumor Ag (T Ag)-transformed cells. Immunization of B6 mice with wild-type T Ag-transformed cells primes T(CD8) specific for three immunodominant T Ag epitopes (epitopes I, II/III, and IV) but fails to induce T(CD8) specific for the subdominant T Ag epitope V. Using adoptively transferred T(CD8) from epitope V-specific TCR transgenic mice and immunization with T Ag-transformed cells, we demonstrate that the subdominant epitope V is weakly cross-presented relative to immunodominant epitopes derived from the same protein Ag. Priming of naive epitope V-specific TCR transgenic T(CD8) in B6 mice required cross-presentation by host APC. However, robust expansion of these T(CD8) required additional direct presentation of the subdominant epitope by T Ag-transformed cells and was only significant following immunization with T Ag-expressing cells lacking the immunodominant epitopes. These results indicate that limited cross-presentation coupled with competition by immunodominant epitope-specific T(CD8) contributes to the subdominant nature of a tumor-specific epitope. This finding has implications for vaccination strategies targeting T(CD8) responses to cancer.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16002665     DOI: 10.4049/jimmunol.175.2.700

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  18 in total

1.  CD8+ T cell immunodominance in lymphocytic choriomeningitis virus infection is modified in the presence of toll-like receptor agonists.

Authors:  Sarah Siddiqui; Sameh Basta
Journal:  J Virol       Date:  2011-09-28       Impact factor: 5.103

2.  Exosome-driven antigen transfer for MHC class II presentation facilitated by the receptor binding activity of influenza hemagglutinin.

Authors:  James S Testa; Geraud S Apcher; Joseph D Comber; Laurence C Eisenlohr
Journal:  J Immunol       Date:  2010-11-03       Impact factor: 5.422

3.  Identification of Mycobacterium tuberculosis PPE68-specific HLA-A*0201-restricted epitopes for tuberculosis diagnosis.

Authors:  Zhi-Liang Duan; Qiang Li; Sina Wang; Xin-Yu Chen; Hui-Fang Liu; Bo-Kun Chen; De-Zhou Li; Xi Huang; Jin-Sheng Wen
Journal:  Curr Microbiol       Date:  2015-02-15       Impact factor: 2.188

Review 4.  Victory and defeat in the induction of a therapeutic response through vaccine therapy for human and canine brain tumors: a review of the state of the art.

Authors:  Michael R Olin; G Elizabeth Pluhar; Brian M Andersen; Rob Shaver; Nate N Waldron; Christopher L Moertel
Journal:  Crit Rev Immunol       Date:  2014       Impact factor: 2.214

5.  Hierarchy of alpha fetoprotein (AFP)-specific T cell responses in subjects with AFP-positive hepatocellular cancer.

Authors:  Yang Liu; Sean Daley; Viktoria N Evdokimova; David D Zdobinski; Douglas M Potter; Lisa H Butterfield
Journal:  J Immunol       Date:  2006-07-01       Impact factor: 5.422

6.  Delivery of Exogenous Antigens to Induce Cytotoxic CD8+ T Lymphocyte Responses.

Authors:  Julia Kim; Vandana Gambhir; Attiya Alatery; Sameh Basta
Journal:  J Biomed Biotechnol       Date:  2010-05-23

7.  CD8+ T cells targeting a single immunodominant epitope are sufficient for elimination of established SV40 T antigen-induced brain tumors.

Authors:  Angela M Tatum; Lawrence M Mylin; Susan J Bender; Matthew A Fischer; Beth A Vigliotti; M Judith Tevethia; Satvir S Tevethia; Todd D Schell
Journal:  J Immunol       Date:  2008-09-15       Impact factor: 5.422

8.  Epitope-specific regulation of memory programming by differential duration of antigen presentation to influenza-specific CD8(+) T cells.

Authors:  André Ballesteros-Tato; Beatriz León; Byung O Lee; Frances E Lund; Troy D Randall
Journal:  Immunity       Date:  2014-07-17       Impact factor: 31.745

9.  A novel human-derived antibody against NY-ESO-1 improves the efficacy of chemotherapy.

Authors:  Anurag Gupta; Natko Nuber; Christoph Esslinger; Mareike Wittenbrink; Martin Treder; Alexandro Landshammer; Takuro Noguchi; Marcus Kelly; Sacha Gnjatic; Erika Ritter; Lotta von Boehmer; Hiroyoshi Nishikawa; Hiroshi Shiku; Lloyd Old; Gerd Ritter; Alexander Knuth; Maries van den Broek
Journal:  Cancer Immun       Date:  2013-01-15

10.  Combined anti-CD40 conditioning and well-timed immunization prolongs CD8+ T cell accumulation and control of established brain tumors.

Authors:  Christina M Ryan; Kevin Staveley-O'Carroll; Todd D Schell
Journal:  J Immunother       Date:  2008 Nov-Dec       Impact factor: 4.456

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.